Open AccessHigh-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates
Author(s) -
Jihad Inshasi,
Abubaker Almadani,
Sarmad Al Fahad,
Suzan Noori,
Taoufik Alsaadi,
Mustafa Shakra,
Ahmed Shatila,
Tayseer Zein,
Amir Boshra
Publication year - 2020
Publication title -
neurodegenerative disease management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.674
H-Index - 23
eISSN - 1758-2032
pISSN - 1758-2024
DOI - 10.2217/nmt-2020-0016
Subject(s) - tolerability , medicine , multiple sclerosis , relapsing remitting , expert opinion , intensive care medicine , adverse effect , psychiatry , pharmacology
The number of disease-modifying treatments (DMDs) for relapsing-remitting multiple sclerosis has increased. DMDs differ not only in their efficacy and safety/tolerability, but also in the treatment burden of, associated with their initiation, route/frequency of administration, maintenance treatment and monitoring. High-efficacy DMDs bring the prospect of improved suppression of relapses and progression of disability, but may have serious safety issues, and burdensome long-term monitoring. Studies of patient preferences in this area have focused on side effects, efficacy and route of administration. Adherence to DMDs is often suboptimal in relapsing-remitting multiple sclerosis and there is a need to understand more about how the complex therapeutic and administration profiles of newer DMDs interact with these barriers to support optimal adherence to therapy.